CDC Advisory Committee Modifies Hepatitis B Vaccine Recommendation

The Advisory Committee on Immunization Practices (ACIP) at the U.S. Centers for Disease Control and Prevention (CDC) recently voted to modify its previous guidance regarding the hepatitis B vaccine. The new decision, which passed with an 8-3 vote, encourages a more personalized approach for parents of infants who test negative for hepatitis B, rather than mandating that the first dose be administered within 24 hours of birth.

Despite this shift, the committee maintains that newborns born to mothers with hepatitis B should still receive the vaccine right at birth. This change reflects a new dynamic within the committee, influenced by recent appointments made by Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., who has been vocal in his criticisms of certain childhood vaccination protocols.

It’s important to note that this vote does not immediately alter current policies. The decision requires further approval from Acting CDC Director Jim O’Neill or officials at HHS to take effect. For now, coverage for vaccines through insurance plans remains unchanged.

The committee advised parents choosing to postpone the birth dose to wait until their child is at least two months old and recommended consulting with pediatricians about antibody testing during the subsequent doses.

However, the vote underscores a rift within the committee. Some members voiced significant concerns about how these changes could potentially jeopardize public health. Hilary Blackburn, a panelist in favor of the recommendation, stated that flexibility in decisions promotes access and coverage. On the flip side, Cody Meissner, who opposed the change, articulated moral concerns, arguing that the revised guidelines could inflict harm.

Meissner underscored that the reduction in hepatitis B cases is attributable to the effectiveness of the vaccine, which has shown remarkable success since the introduction of a three-dose regimen in 1991. He went on to warn that altering vaccination practices could lead to a resurgence of hepatitis B infections.

Joe Hibeln, another panelist, expressed his concern for the potential consequences, cautioning against making decisions based solely on current low infection rates. He, too, voted against the motion.

This recommendation has drawn criticism from some Republican lawmakers. For instance, Senator Bill Cassidy of Louisiana, who is also a hepatologist, claimed the committee’s recommendation is misguided, reinforcing that the hepatitis B vaccine is both safe and effective. He emphasized the importance of administering the vaccine at birth.

The vaccines available in the U.S. for hepatitis B—like Engerix-B, Recombivax HB, Heplisav-B, and pediatric formulations—are considered traditional non-live vaccines, unrelated to mRNA technology used in COVID-19 vaccines.